New evidence on the management of spondyloarthritis

Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality

(2015) Nisha Nigil Haroon et al.   ANNALS OF INTERNAL MEDICINE

SAT0258 Baseline MRI/CRP as Predictors of Response to Etanercept in the Management of Patients with Non-Radiographic Axial Spondyloarthritis: Table 1

(2015) M.A. Brown et al.   ANNALS OF THE RHEUMATIC DISEASES

The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study

(2015) Elisabeth Lie et al.   ANNALS OF THE RHEUMATIC DISEASES

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

(2015) K. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

(2015) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

(2015) J. Sieper et al.   Arthritis & Rheumatology

A Randomized, Double-Blind, Placebo-Controlled, Sixteen-Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis

(2015) J. Sieper et al.   Arthritis & Rheumatology

Brief Report: Nonsteroidal Antiinflammatory Drug-Sparing Effect of Tumor Necrosis Factor Inhibitors in Early Axial Spondyloarthritis: Results From the DESIR Cohort

(2015) Anna Moltó et al.   Arthritis & Rheumatology

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis

(2015) Philip Mease et al.   Arthritis & Rheumatology

Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohor

(2015) Denis Poddubnyy et al.   Arthritis & Rheumatology

American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

(2015) Michael M. Ward et al.   Arthritis & Rheumatology

Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)

(2014) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort

(2014) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

(2014) Denis Poddubnyy et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

(2014) Jackie L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study

(2014) Maxime Dougados et al.   ARTHRITIS RESEARCH & THERAPY

Effectiveness of Tumor Necrosis Factor α Blockers in Early Axial Spondyloarthritis: Data From the DESIR Cohort

(2014) Anna Moltó et al.   Arthritis & Rheumatology

Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Maxime Dougados et al.   Arthritis & Rheumatology

A178: Development of Tools to Facilitate Shared Decision Making about Medications for Juvenile Idiopathic Arthritis-A Project of the Pediatric Rheumatology Care and Outcomes Improvement Network

(2014) Esi Morgan DeWitt et al.   Arthritis & Rheumatology

The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns

(2014) Atul Deodhar et al.   Arthritis & Rheumatology

Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2

(2013) J Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

(2013) R Landewé et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial

(2013) H Haibel et al.   ANNALS OF THE RHEUMATIC DISEASES

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

(2013) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial

(2013) Jürgen Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort

(2013) Liesbet Van Praet et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1

(2013) J Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis

(2013) Xenofon Baraliakos et al.   ANNALS OF THE RHEUMATIC DISEASES

Tumor Necrosis Factor α Inhibition in Radiographic and Nonradiographic Axial Spondyloarthritis: Results From a Large Observational Cohort

(2013) Adrian Ciurea et al.   ARTHRITIS AND RHEUMATISM

Long-Term Efficacy of Adalimumab After Drug Withdrawal and Retreatment in Patients With Active Non-Radiographically Evident Axial Spondyloarthritis Who Experience a Flare

(2013) H. Haibel et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

(2013) Dominique Baeten et al.   LANCET

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

(2013)   LANCET

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

(2012) Fabien B Vincent et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)

(2012) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial

(2012) In-Ho Song et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis

(2012) Jacqueline E Paramarta et al.   ANNALS OF THE RHEUMATIC DISEASES

Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis

(2012) Féline Kroon et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort

(2012) Denis Poddubnyy et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Developments in therapies for spondyloarthritis

(2012) Joachim Sieper   Nature Reviews Rheumatology

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial

(2011) I.-H. Song et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

(2011) D. van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Increased mortality in ankylosing spondylitis is related to disease activity

(2011) G. Bakland et al.   ANNALS OF THE RHEUMATIC DISEASES

Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis

(2011) D. Poddubnyy et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study

(2011) I.-H. Song et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

(2011) J. Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial

(2011) Juergen Braun et al.   ARTHRITIS AND RHEUMATISM

Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis

(2011) Denis Poddubnyy et al.   ARTHRITIS AND RHEUMATISM

A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial

(2010) M. Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

(2010) P. Machado et al.   ANNALS OF THE RHEUMATIC DISEASES

The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general

(2010) M. Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial

(2010) I.-H. Song et al.   ARTHRITIS AND RHEUMATISM

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

(2009) M Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)

(2009) J Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis

(2009) John D. Carter et al.   ARTHRITIS AND RHEUMATISM

Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis

(2009) Nick Barkham et al.   ARTHRITIS AND RHEUMATISM

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

(2009) Désirée van der Heijde et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two

(2008) Hildrun Haibel et al.   ARTHRITIS AND RHEUMATISM

Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs

(2008) I. H. Song et al.   ARTHRITIS AND RHEUMATISM

The comparative one-year performance of anti–tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study

(2008) Marte Schrumpf Heiberg et al.   ARTHRITIS AND RHEUMATISM

Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes

(2008) Joachim Sieper et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial

(2008) Robert D. Inman et al.   ARTHRITIS AND RHEUMATISM

Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept

(2008) D. van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET